Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Evaluation of US Federal Guidelines (Primary Response Incident Scene Management [PRISM]) for Mass Decontamination of Casualties During the Initial Operational Response to a Chemical Incident.

Chilcott RP, Larner J, Durrant A, Hughes P, Mahalingam D, Rivers S, Thomas E, Amer N, Barrett M, Matar H, Pinhal A, Jackson T, McCarthy-Barnett K, Reppucci J.

Ann Emerg Med. 2018 Aug 23. pii: S0196-0644(18)30573-0. doi: 10.1016/j.annemergmed.2018.06.042. [Epub ahead of print]

2.

Case report of prostate ductal adenocarcinoma presenting with hematuria.

Pawlowski J, Swanson GP, Mahalingam D, Ha CS.

Urol Case Rep. 2018 May 12;19:63-64. doi: 10.1016/j.eucr.2018.05.013. eCollection 2018 Jul. No abstract available.

3.

A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma.

Mahalingam D, Goel S, Aparo S, Patel Arora S, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Gutierrez A, Coffey M, Nawrocki ST, Nuovo G, Mita MM.

Cancers (Basel). 2018 May 25;10(6). pii: E160. doi: 10.3390/cancers10060160.

4.

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer.

Costa RB, Costa RLB, Talamantes SM, Kaplan JB, Bhave MA, Rademaker A, Miller C, Carneiro BA, Mahalingam D, Chae YK.

Oncotarget. 2018 Apr 24;9(31):22137-22146. doi: 10.18632/oncotarget.25154. eCollection 2018 Apr 24.

5.

Immunotherapy in colorectal cancer: for the select few or all?

Arora SP, Mahalingam D.

J Gastrointest Oncol. 2018 Feb;9(1):170-179. doi: 10.21037/jgo.2017.06.10. Review.

6.

Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response.

Rosenberg A, Mahalingam D.

J Gastrointest Oncol. 2018 Feb;9(1):143-159. doi: 10.21037/jgo.2018.01.13. Review.

7.

The coming of age: immunotherapy in gastrointestinal malignancies.

Mahalingam D.

J Gastrointest Oncol. 2018 Feb;9(1):140-142. doi: 10.21037/jgo.2018.02.01. No abstract available.

8.

Review: Oncolytic virotherapy, updates and future directions.

Fountzilas C, Patel S, Mahalingam D.

Oncotarget. 2017 May 31;8(60):102617-102639. doi: 10.18632/oncotarget.18309. eCollection 2017 Nov 24. Review.

9.

Correlation of tumor mutational burden and treatment outcomes in patients with colorectal cancer.

Pai SG, Carneiro BA, Chae YK, Costa RL, Kalyan A, Shah HA, Helenowski I, Rademaker AW, Mahalingam D, Giles FJ.

J Gastrointest Oncol. 2017 Oct;8(5):858-866. doi: 10.21037/jgo.2017.06.20.

10.

Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx®): a placebo-controlled randomised phase II study (PLIANT).

Glimelius B, Manojlovic N, Pfeiffer P, Mosidze B, Kurteva G, Karlberg M, Mahalingam D, Buhl Jensen P, Kowalski J, Bengtson M, Nittve M, Näsström J.

Acta Oncol. 2018 Mar;57(3):393-402. doi: 10.1080/0284186X.2017.1398836. Epub 2017 Nov 15.

PMID:
29140155
11.

Left Versus Right: Does Location Matter for Refractory Metastatic Colorectal Cancer Patients in Phase 1 Clinical Trials?

Arora SP, Ketchum NS, Michalek J, Gelfond J, Mahalingam D.

J Gastrointest Cancer. 2018 Sep;49(3):283-287. doi: 10.1007/s12029-017-9948-3.

PMID:
28432610
12.

Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence.

Sunkel B, Wu D, Chen Z, Wang CM, Liu X, Ye Z, Horning AM, Liu J, Mahalingam D, Lopez-Nicora H, Lin CL, Goodfellow PJ, Clinton SK, Jin VX, Chen CL, Huang TH, Wang Q.

Nucleic Acids Res. 2017 Jun 20;45(11):6993. doi: 10.1093/nar/gkx282. No abstract available.

13.

A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma.

Mahalingam D, Fountzilas C, Moseley J, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Coffey M, Thompson B, Sarantopoulos J.

Cancer Chemother Pharmacol. 2017 Apr;79(4):697-703. doi: 10.1007/s00280-017-3260-6. Epub 2017 Mar 13.

PMID:
28289863
14.

Clinical characteristics and treatment outcomes of patients with colorectal cancer who develop brain metastasis: a single institution experience.

Fountzilas C, Chang K, Hernandez B, Michalek J, Crownover R, Floyd J, Mahalingam D.

J Gastrointest Oncol. 2017 Feb;8(1):55-63. doi: 10.21037/jgo.2016.12.11.

15.

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development.

Costa R, Shah AN, Santa-Maria CA, Cruz MR, Mahalingam D, Carneiro BA, Chae YK, Cristofanilli M, Gradishar WJ, Giles FJ.

Cancer Treat Rev. 2017 Feb;53:111-119. doi: 10.1016/j.ctrv.2016.12.010. Epub 2017 Jan 5. Review.

PMID:
28104566
16.

Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?

Fountzilas C, Stuart S, Hernandez B, Bowhay-Carnes E, Michalek J, Sarantopoulos J, Karnad A, Patel S, Weitman S, Mahalingam D.

Invest New Drugs. 2017 Jun;35(3):386-391. doi: 10.1007/s10637-017-0425-4. Epub 2017 Jan 19.

PMID:
28102465
17.

TGF-β signal rewiring sustains epithelial-mesenchymal transition of circulating tumor cells in prostate cancer xenograft hosts.

Huang G, Osmulski PA, Bouamar H, Mahalingam D, Lin CL, Liss MA, Kumar AP, Chen CL, Thompson IM, Sun LZ, Gaczynska ME, Huang TH.

Oncotarget. 2016 Nov 22;7(47):77124-77137. doi: 10.18632/oncotarget.12808.

18.

First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.

Menke-van der Houven van Oordt CW, Gomez-Roca C, van Herpen C, Coveler AL, Mahalingam D, Verheul HM, van der Graaf WT, Christen R, Rüttinger D, Weigand S, Cannarile MA, Heil F, Brewster M, Walz AC, Nayak TK, Guarin E, Meresse V, Le Tourneau C.

Oncotarget. 2016 Nov 29;7(48):80046-80058. doi: 10.18632/oncotarget.11098.

19.

Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.

Patel S, Hurez V, Nawrocki ST, Goros M, Michalek J, Sarantopoulos J, Curiel T, Mahalingam D.

Oncotarget. 2016 Sep 13;7(37):59087-59097. doi: 10.18632/oncotarget.10824.

20.

Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.

Mahalingam D, Wilding G, Denmeade S, Sarantopoulas J, Cosgrove D, Cetnar J, Azad N, Bruce J, Kurman M, Allgood VE, Carducci M.

Br J Cancer. 2016 Apr 26;114(9):986-94. doi: 10.1038/bjc.2016.72.

21.

Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes.

Wang CP, Lehman DM, Lam YF, Kuhn JG, Mahalingam D, Weitman S, Lorenzo C, Downs JR, Stuart EA, Hernandez J, Thompson IM, Ramirez AG.

Cancer Prev Res (Phila). 2016 Oct;9(10):779-787. Epub 2016 Mar 29.

22.

Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence.

Sunkel B, Wu D, Chen Z, Wang CM, Liu X, Ye Z, Horning AM, Liu J, Mahalingam D, Lopez-Nicora H, Lin CL, Goodfellow PJ, Clinton SK, Jin VX, Chen CL, Huang TH, Wang Q.

Nucleic Acids Res. 2016 May 19;44(9):4105-22. doi: 10.1093/nar/gkv1528. Epub 2016 Jan 6.

23.

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.

Falchook GS, Zhou X, Venkatakrishnan K, Kurzrock R, Mahalingam D, Goldman JW, Jung J, Ullmann CD, Milch C, Rosen LS, Sarantopoulos J.

Drugs R D. 2016 Mar;16(1):45-52. doi: 10.1007/s40268-015-0114-8.

24.

Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer.

Mishra S, Tai Q, Gu X, Schmitz J, Poullard A, Fajardo RJ, Mahalingam D, Chen X, Zhu X, Sun LZ.

Oncotarget. 2015 Dec 29;6(42):44388-402. doi: 10.18632/oncotarget.6317.

25.

Advanced Cancer Patients' Understanding and Perceptions of Phase I Clinical Trials.

Pawlowski J, Malik L, Mahalingam D.

Cancer Invest. 2015;33(10):490-5. doi: 10.3109/07357907.2015.1069833. Epub 2015 Oct 13.

PMID:
26460889
26.

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.

Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel HM, Berger AJ, Burke K, Mulligan G, Dezube BJ, Harvey RD.

Clin Cancer Res. 2016 Feb 15;22(4):847-57. doi: 10.1158/1078-0432.CCR-15-1338. Epub 2015 Sep 30.

27.

The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.

Mahalingam D, Patel S, Nuovo G, Gill G, Selvaggi G, Coffey M, Nawrocki ST.

BMC Cancer. 2015 Jul 10;15:513. doi: 10.1186/s12885-015-1518-0.

28.

Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction.

Al-Rajabi R, Patel S, Ketchum NS, Jaime NA, Lu TW, Pollock BH, Mahalingam D.

J Gastrointest Oncol. 2015 Jun;6(3):259-67. doi: 10.3978/j.issn.2078-6891.2015.005.

29.

CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.

Birzele F, Voss E, Nopora A, Honold K, Heil F, Lohmann S, Verheul H, Le Tourneau C, Delord JP, van Herpen C, Mahalingam D, Coveler AL, Meresse V, Weigand S, Runza V, Cannarile M.

Clin Cancer Res. 2015 Jun 15;21(12):2753-62. doi: 10.1158/1078-0432.CCR-14-2141. Epub 2015 Mar 11.

30.

Emergency Medical Text Classifier: New system improves processing and classification of triage notes.

Haas SW, Travers D, Waller A, Mahalingam D, Crouch J, Schwartz TA, Mostafa J.

Online J Public Health Inform. 2014 Oct 16;6(2):e178. doi: 10.5210/ojphi.v6i2.5469. eCollection 2014.

31.

Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.

Mahalingam D, Nemunaitis JJ, Malik L, Sarantopoulos J, Weitman S, Sankhala K, Hart J, Kousba A, Gallegos NS, Anderson G, Charles J, Rogers JM, Senzer NN, Mita AC.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1241-50. doi: 10.1007/s00280-014-2602-x. Epub 2014 Oct 11.

PMID:
25304209
32.

Predicting success in regulatory approval from Phase I results.

Malik L, Mejia A, Parsons H, Ehler B, Mahalingam D, Brenner A, Sarantopoulos J, Weitman S.

Cancer Chemother Pharmacol. 2014 Nov;74(5):1099-103. doi: 10.1007/s00280-014-2596-4. Epub 2014 Sep 23.

33.

Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer.

Osmulski P, Mahalingam D, Gaczynska ME, Liu J, Huang S, Horning AM, Wang CM, Thompson IM, Huang TH, Chen CL.

Prostate. 2014 Sep;74(13):1297-307. doi: 10.1002/pros.22846. Epub 2014 Jul 25.

34.

Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.

Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi RK, Davis LE, Mita AC, Curiel TJ, Espitia CM, Nawrocki ST, Giles FJ, Carew JS.

Autophagy. 2014 Aug;10(8):1403-14. doi: 10.4161/auto.29231. Epub 2014 May 20.

35.

Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.

Mahalingam D, Malik L, Beeram M, Rodon J, Sankhala K, Mita A, Benjamin D, Ketchum N, Michalek J, Tolcher A, Wright J, Sarantopoulos J.

Cancer Chemother Pharmacol. 2014 Jul;74(1):77-84. doi: 10.1007/s00280-014-2479-8. Epub 2014 May 10.

PMID:
24817603
36.

Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials.

Patel SR, Karnad AB, Ketchum NS, Pollock BH, Sarantopoulos J, Weitman S, Mahalingam D.

J Gastrointest Oncol. 2014 Apr;5(2):99-103. doi: 10.3978/j.issn.2078-6891.2014.002.

37.

Clinical outcomes and survival of advanced renal cancer patients in phase I clinical trials.

Malik L, Parsons H, Mahalingam D, Ehler B, Goros M, Mejia A, Brenner A, Sarantopoulos J.

Clin Genitourin Cancer. 2014 Oct;12(5):359-65. doi: 10.1016/j.clgc.2014.01.011. Epub 2014 Feb 4.

38.

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.

Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC.

Clin Cancer Res. 2014 Apr 1;20(7):1900-9. doi: 10.1158/1078-0432.CCR-13-1710. Epub 2014 Feb 12.

39.

Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.

Gowda PS, Deng JD, Mishra S, Bandyopadhyay A, Liang S, Lin S, Mahalingam D, Sun LZ.

Mol Cancer Res. 2013 Nov;11(11):1448-61. doi: 10.1158/1541-7786.MCR-13-0278. Epub 2013 Aug 29.

40.

Supplementation with natural forms of vitamin E augments antigen-specific TH1-type immune response to tetanus toxoid.

Radhakrishnan AK, Mahalingam D, Selvaduray KR, Nesaretnam K.

Biomed Res Int. 2013;2013:782067. doi: 10.1155/2013/782067. Epub 2013 Jul 7.

41.

Elite model for the generation of induced pluripotent cancer cells (iPCs).

Lai J, Kong CM, Mahalingam D, Xie X, Wang X.

PLoS One. 2013;8(2):e56702. doi: 10.1371/journal.pone.0056702. Epub 2013 Feb 13.

42.

Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.

Chen CL, Mahalingam D, Osmulski P, Jadhav RR, Wang CM, Leach RJ, Chang TC, Weitman SD, Kumar AP, Sun L, Gaczynska ME, Thompson IM, Huang TH.

Prostate. 2013 Jun;73(8):813-26. doi: 10.1002/pros.22625. Epub 2012 Dec 31.

43.

Reversal of aberrant cancer methylome and transcriptome upon direct reprogramming of lung cancer cells.

Mahalingam D, Kong CM, Lai J, Tay LL, Yang H, Wang X.

Sci Rep. 2012;2:592. doi: 10.1038/srep00592. Epub 2012 Aug 21.

44.

Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.

Rosen LS, Puzanov I, Friberg G, Chan E, Hwang YC, Deng H, Gilbert J, Mahalingam D, McCaffery I, Michael SA, Mita AC, Mita MM, Mulay M, Shubhakar P, Zhu M, Sarantopoulos J.

Clin Cancer Res. 2012 Jun 15;18(12):3414-27. doi: 10.1158/1078-0432.CCR-11-3369. Epub 2012 Apr 17.

45.

Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL.

Szegezdi E, van der Sloot AM, Mahalingam D, O'Leary L, Cool RH, Muñoz IG, Montoya G, Quax WJ, de Jong S, Samali A, Serrano L.

Mol Cell Proteomics. 2012 Mar;11(3):M111.013730. doi: 10.1074/mcp.M111.013730. Epub 2012 Jan 2.

46.

Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.

Mahalingam D, Espitia CM, Medina EC, Esquivel JA 2nd, Kelly KR, Bearss D, Choy G, Taverna P, Carew JS, Giles FJ, Nawrocki ST.

Br J Cancer. 2011 Nov 8;105(10):1563-73. doi: 10.1038/bjc.2011.426. Epub 2011 Oct 20.

47.

Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma.

Kelly KR, Espitia CM, Mahalingam D, Oyajobi BO, Coffey M, Giles FJ, Carew JS, Nawrocki ST.

Oncogene. 2012 Jun 21;31(25):3023-38. doi: 10.1038/onc.2011.478. Epub 2011 Oct 17.

PMID:
22002308
48.

Mutant telomerase RNAs induce DNA damage and apoptosis via the TRF2-ATM pathway in telomerase-overexpressing primary fibroblasts.

Mahalingam D, Tay LL, Tan WH, Chai JH, Wang X.

FEBS J. 2011 Oct;278(19):3724-38. doi: 10.1111/j.1742-4658.2011.08290.x. Epub 2011 Sep 6. Erratum in: FEBS J. 2012 Jan;279(2):358.

49.

Targeting aurora kinases in cancer treatment.

Kelly KR, Ecsedy J, Mahalingam D, Nawrocki ST, Padmanabhan S, Giles FJ, Carew JS.

Curr Drug Targets. 2011 Dec;12(14):2067-78. Review.

PMID:
21777198
50.

The Pim kinases: new targets for drug development.

Swords R, Kelly K, Carew J, Nawrocki S, Mahalingam D, Sarantopoulos J, Bearss D, Giles F.

Curr Drug Targets. 2011 Dec;12(14):2059-66. Review.

PMID:
21777193

Supplemental Content

Loading ...
Support Center